Literature DB >> 2504087

Fibrinolysis in critically ill patients.

R Moalli1, J M Doyle, H R Tahhan, F M Hasan, S S Braman, T Saldeen.   

Abstract

Impaired fibrinolysis may contribute to development of adult respiratory distress syndrome (ARDS). Pathologic increases in endogenous plasminogen activator inhibitor (PAI-1) may blunt normal fibrinolysis and unmask alternate fibrinolytic mechanisms, such as elastase-induced fibrin degradation. We measured PAI-1 and elastase-induced fibrin(ogen) degradation products in 69 critically ill patients in our medical intensive care unit (MICU) and in nine healthy volunteers. Factor VIII-related antigen protein (VIII:Ag), a reported marker of acute lung injury, and alpha-1-protease inhibitor (alpha-1-PI), an acute phase reactant, were also measured. MICU patients included 24 control patients with no known risk of ARDS, 35 patients with risk factors for ARDS including sepsis, pneumonia, aspiration, and shock, and 12 patients with ARDS including two patients from at-risk groups who developed ARDS. Plasma PAI-1 was determined by chromogenic assay, elastase-induced peptides by a new radioimmunoassay, VIII:Ag by immunoelectrophoresis, and alpha-1-PI by immunodiffusion. When compared to normal volunteers, MICU control patients had elevated PAI-1, VIII:Ag, elastase-induced peptides, and alpha-1-PI. Patients with ARDS had significantly higher PAI-1 and VIII:Ag than did MICU control patients; elastase-induced peptides and alpha-1-PI were not higher. However, at-risk patients who did not develop ARDS also had high PAI-1 or VIII:Ag. Although these data cannot refute the possible role of these compounds in the pathogenesis of ARDS, they demonstrate that PAI-1 and VIII:Ag may be elevated in many critically ill patients but may not be useful markers for the subsequent development of ARDS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504087     DOI: 10.1164/ajrccm/140.2.287

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation.

Authors:  Heidi R Flori; Lorraine B Ware; Meredith Milet; Michael A Matthay
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

Review 2.  Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome.

Authors:  Sara C Sebag; Julie A Bastarache; Lorraine B Ware
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

3.  Monitoring of immunotherapy with cytokines or monoclonal antibodies.

Authors:  C Erik Hack
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

4.  Enhanced fibrinolysis protects against lung ischemia-reperfusion injury.

Authors:  Christine L Lau; Yunge Zhao; Jiyoun Kim; Irving L Kron; Ashish Sharma; Zequan Yang; Victor E Laubach; Joel Linden; Gorav Ailawadi; David J Pinsky
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05       Impact factor: 5.209

Review 5.  Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome.

Authors:  Robert MacLaren; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

Review 6.  Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator.

Authors:  Argyris Tzouvelekis; Ioannis Pneumatikos; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-06-22

7.  Association between inflammatory biomarkers and acute respiratory distress syndrome or acute lung injury risk : A systematic review and meta-analysis.

Authors:  Zhenfeng Liu; Daishun Liu; Zhihua Wang; Yugang Zou; Haixia Wang; Xiao Li; Deliang Zheng; Guoqi Zhou
Journal:  Wien Klin Wochenschr       Date:  2021-12-03       Impact factor: 1.704

8.  Elevated plasma D-dimer levels are associated with the poor prognosis of critically ill children.

Authors:  Guan Wang; Junhui Liu; Rui Xu; Xinjie Liu
Journal:  Front Pediatr       Date:  2022-09-23       Impact factor: 3.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.